New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function

Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder. Cognitive impairment is a core symptom in patients with the illness, and has been suggested a major predictor of functional outcomes. Reduction of parvalbumin (PV)-positive ?-aminobutyric acid (GABA) interneurons has be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current neuropharmacology 2015-01, Vol.13 (6), p.793-801
Hauptverfasser: Uehara, Takashi, Sumiyoshi, Tomiki, Kurachi, Masayoshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 801
container_issue 6
container_start_page 793
container_title Current neuropharmacology
container_volume 13
creator Uehara, Takashi
Sumiyoshi, Tomiki
Kurachi, Masayoshi
description Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder. Cognitive impairment is a core symptom in patients with the illness, and has been suggested a major predictor of functional outcomes. Reduction of parvalbumin (PV)-positive ?-aminobutyric acid (GABA) interneurons has been associated with the pathophysiology of schizophrenia, in view of the link between the abnormality of GABA neurons and cognitive impairments of the disease. It is assumed that an imbalance of excitatory and inhibitory (E-I) activity induced by low activity of glutamatergic projections and PV-positive GABA interneurons in the prefrontal cortex resulted in sustained neural firing and gamma oscillation, leading to impaired cognitive function. Therefore, it is important to develop novel pharmacotherapy targeting GABA neurons and their activities. Clinical evidence suggests serotonin (5-HT) 1A receptor agonist improves cognitive disturbances of schizophrenia, consistent with results from preclinical studies, through mechanism that corrects E-I imbalance via the suppression of GABA neural function. On the other hand, T-817MA, a novel neurotrophic agent, ameliorated loss of PV-positive GABA neurons in the medial prefrontal cortex and reduction of gamma-band activity, as well as cognitive dysfunction in animal model of schizophrenia. In conclusion, a pharmacotherapy to alleviate abnormalities in GABA neurons through 5-HT 1A agonists and T-817MA is expected to prevent the onset and/or progression of schizophrenia.
doi_str_mv 10.2174/1570159x13666151009120153
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4759318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1744660030</sourcerecordid><originalsourceid>FETCH-LOGICAL-b703t-85e1dc6e2c2a80aec882e724a12fce1722d00aee72887be3d97bf724597707493</originalsourceid><addsrcrecordid>eNqFkUGP0zAQhSMEYpeFv4DCjUvBdhLbuSCVwi5Iy4LEIu1t5LqTxJDYWdtpKWd-OC7tViAOHCyP5n1vNKOXZc8oecGoKF_SShBa1d9pwTmnFSWkpix1invZKZWimnFak_upTtwsgTcn2aMQvhLCKsnEw-yEcV6QuhKn2XCFm_xTp_ygtIsdejVu82vlW4zGtvnCtdZEs8b8zTY0k9XROJu7Jv-sO_PDjZ1Ha1S-Tu-DW029utMv5q_n-RVO3lnV5-cH5-PsQaP6gE8O_1n25fzt9eLd7PLjxfvF_HK2FKSIM1khXWmOTDMliUItJUPBSkVZo5EKxlYktVNLSrHEYlWLZZP0qhaCiLIuzrJX-7njtBxwpdFGr3oYvRmU34JTBv5WrOmgdWsoRVUXVKYBzw8DvLudMEQYTNDY98qimwJQSaSgpeDl_1FRlpwTUpCE1ntUexeCx-a4ESWwSxYOyd78k2zyPv3zpKPzLsoE_NwDy3RTp4agDVqNR7CLcYTNZgMpFPymAvaoI2g3gBvRTr5PtY3JC2M3QovWIygfje4RTAj2926wWw7Wrp8GBFrshAmBQxhViyDqovgFXSrULg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1744660030</pqid></control><display><type>article</type><title>New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Uehara, Takashi ; Sumiyoshi, Tomiki ; Kurachi, Masayoshi</creator><creatorcontrib>Uehara, Takashi ; Sumiyoshi, Tomiki ; Kurachi, Masayoshi</creatorcontrib><description>Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder. Cognitive impairment is a core symptom in patients with the illness, and has been suggested a major predictor of functional outcomes. Reduction of parvalbumin (PV)-positive ?-aminobutyric acid (GABA) interneurons has been associated with the pathophysiology of schizophrenia, in view of the link between the abnormality of GABA neurons and cognitive impairments of the disease. It is assumed that an imbalance of excitatory and inhibitory (E-I) activity induced by low activity of glutamatergic projections and PV-positive GABA interneurons in the prefrontal cortex resulted in sustained neural firing and gamma oscillation, leading to impaired cognitive function. Therefore, it is important to develop novel pharmacotherapy targeting GABA neurons and their activities. Clinical evidence suggests serotonin (5-HT) 1A receptor agonist improves cognitive disturbances of schizophrenia, consistent with results from preclinical studies, through mechanism that corrects E-I imbalance via the suppression of GABA neural function. On the other hand, T-817MA, a novel neurotrophic agent, ameliorated loss of PV-positive GABA neurons in the medial prefrontal cortex and reduction of gamma-band activity, as well as cognitive dysfunction in animal model of schizophrenia. In conclusion, a pharmacotherapy to alleviate abnormalities in GABA neurons through 5-HT 1A agonists and T-817MA is expected to prevent the onset and/or progression of schizophrenia.</description><identifier>ISSN: 1570-159X</identifier><identifier>EISSN: 1875-6190</identifier><identifier>DOI: 10.2174/1570159x13666151009120153</identifier><identifier>PMID: 26630957</identifier><language>eng</language><publisher>United Arab Emirates: Bentham Science Publishers Ltd</publisher><subject>Animals ; Cognition Disorders - complications ; Cognition Disorders - drug therapy ; Cognition Disorders - metabolism ; gamma-Aminobutyric Acid - metabolism ; Humans ; Psychotropic Drugs - pharmacology ; Psychotropic Drugs - therapeutic use ; Receptor, Serotonin, 5-HT1A - metabolism ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Schizophrenia - metabolism ; Schizophrenic Psychology</subject><ispartof>Current neuropharmacology, 2015-01, Vol.13 (6), p.793-801</ispartof><rights>2015 Bentham Science Publishers 2015 Takashi Uehara</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b703t-85e1dc6e2c2a80aec882e724a12fce1722d00aee72887be3d97bf724597707493</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759318/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759318/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26630957$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uehara, Takashi</creatorcontrib><creatorcontrib>Sumiyoshi, Tomiki</creatorcontrib><creatorcontrib>Kurachi, Masayoshi</creatorcontrib><title>New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function</title><title>Current neuropharmacology</title><addtitle>CN</addtitle><description>Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder. Cognitive impairment is a core symptom in patients with the illness, and has been suggested a major predictor of functional outcomes. Reduction of parvalbumin (PV)-positive ?-aminobutyric acid (GABA) interneurons has been associated with the pathophysiology of schizophrenia, in view of the link between the abnormality of GABA neurons and cognitive impairments of the disease. It is assumed that an imbalance of excitatory and inhibitory (E-I) activity induced by low activity of glutamatergic projections and PV-positive GABA interneurons in the prefrontal cortex resulted in sustained neural firing and gamma oscillation, leading to impaired cognitive function. Therefore, it is important to develop novel pharmacotherapy targeting GABA neurons and their activities. Clinical evidence suggests serotonin (5-HT) 1A receptor agonist improves cognitive disturbances of schizophrenia, consistent with results from preclinical studies, through mechanism that corrects E-I imbalance via the suppression of GABA neural function. On the other hand, T-817MA, a novel neurotrophic agent, ameliorated loss of PV-positive GABA neurons in the medial prefrontal cortex and reduction of gamma-band activity, as well as cognitive dysfunction in animal model of schizophrenia. In conclusion, a pharmacotherapy to alleviate abnormalities in GABA neurons through 5-HT 1A agonists and T-817MA is expected to prevent the onset and/or progression of schizophrenia.</description><subject>Animals</subject><subject>Cognition Disorders - complications</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - metabolism</subject><subject>gamma-Aminobutyric Acid - metabolism</subject><subject>Humans</subject><subject>Psychotropic Drugs - pharmacology</subject><subject>Psychotropic Drugs - therapeutic use</subject><subject>Receptor, Serotonin, 5-HT1A - metabolism</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - metabolism</subject><subject>Schizophrenic Psychology</subject><issn>1570-159X</issn><issn>1875-6190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGP0zAQhSMEYpeFv4DCjUvBdhLbuSCVwi5Iy4LEIu1t5LqTxJDYWdtpKWd-OC7tViAOHCyP5n1vNKOXZc8oecGoKF_SShBa1d9pwTmnFSWkpix1invZKZWimnFak_upTtwsgTcn2aMQvhLCKsnEw-yEcV6QuhKn2XCFm_xTp_ygtIsdejVu82vlW4zGtvnCtdZEs8b8zTY0k9XROJu7Jv-sO_PDjZ1Ha1S-Tu-DW029utMv5q_n-RVO3lnV5-cH5-PsQaP6gE8O_1n25fzt9eLd7PLjxfvF_HK2FKSIM1khXWmOTDMliUItJUPBSkVZo5EKxlYktVNLSrHEYlWLZZP0qhaCiLIuzrJX-7njtBxwpdFGr3oYvRmU34JTBv5WrOmgdWsoRVUXVKYBzw8DvLudMEQYTNDY98qimwJQSaSgpeDl_1FRlpwTUpCE1ntUexeCx-a4ESWwSxYOyd78k2zyPv3zpKPzLsoE_NwDy3RTp4agDVqNR7CLcYTNZgMpFPymAvaoI2g3gBvRTr5PtY3JC2M3QovWIygfje4RTAj2926wWw7Wrp8GBFrshAmBQxhViyDqovgFXSrULg</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Uehara, Takashi</creator><creator>Sumiyoshi, Tomiki</creator><creator>Kurachi, Masayoshi</creator><general>Bentham Science Publishers Ltd</general><general>Bentham Science Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function</title><author>Uehara, Takashi ; Sumiyoshi, Tomiki ; Kurachi, Masayoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b703t-85e1dc6e2c2a80aec882e724a12fce1722d00aee72887be3d97bf724597707493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Cognition Disorders - complications</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - metabolism</topic><topic>gamma-Aminobutyric Acid - metabolism</topic><topic>Humans</topic><topic>Psychotropic Drugs - pharmacology</topic><topic>Psychotropic Drugs - therapeutic use</topic><topic>Receptor, Serotonin, 5-HT1A - metabolism</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - metabolism</topic><topic>Schizophrenic Psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uehara, Takashi</creatorcontrib><creatorcontrib>Sumiyoshi, Tomiki</creatorcontrib><creatorcontrib>Kurachi, Masayoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uehara, Takashi</au><au>Sumiyoshi, Tomiki</au><au>Kurachi, Masayoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function</atitle><jtitle>Current neuropharmacology</jtitle><addtitle>CN</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>13</volume><issue>6</issue><spage>793</spage><epage>801</epage><pages>793-801</pages><issn>1570-159X</issn><eissn>1875-6190</eissn><abstract>Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder. Cognitive impairment is a core symptom in patients with the illness, and has been suggested a major predictor of functional outcomes. Reduction of parvalbumin (PV)-positive ?-aminobutyric acid (GABA) interneurons has been associated with the pathophysiology of schizophrenia, in view of the link between the abnormality of GABA neurons and cognitive impairments of the disease. It is assumed that an imbalance of excitatory and inhibitory (E-I) activity induced by low activity of glutamatergic projections and PV-positive GABA interneurons in the prefrontal cortex resulted in sustained neural firing and gamma oscillation, leading to impaired cognitive function. Therefore, it is important to develop novel pharmacotherapy targeting GABA neurons and their activities. Clinical evidence suggests serotonin (5-HT) 1A receptor agonist improves cognitive disturbances of schizophrenia, consistent with results from preclinical studies, through mechanism that corrects E-I imbalance via the suppression of GABA neural function. On the other hand, T-817MA, a novel neurotrophic agent, ameliorated loss of PV-positive GABA neurons in the medial prefrontal cortex and reduction of gamma-band activity, as well as cognitive dysfunction in animal model of schizophrenia. In conclusion, a pharmacotherapy to alleviate abnormalities in GABA neurons through 5-HT 1A agonists and T-817MA is expected to prevent the onset and/or progression of schizophrenia.</abstract><cop>United Arab Emirates</cop><pub>Bentham Science Publishers Ltd</pub><pmid>26630957</pmid><doi>10.2174/1570159x13666151009120153</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1570-159X
ispartof Current neuropharmacology, 2015-01, Vol.13 (6), p.793-801
issn 1570-159X
1875-6190
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4759318
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Cognition Disorders - complications
Cognition Disorders - drug therapy
Cognition Disorders - metabolism
gamma-Aminobutyric Acid - metabolism
Humans
Psychotropic Drugs - pharmacology
Psychotropic Drugs - therapeutic use
Receptor, Serotonin, 5-HT1A - metabolism
Schizophrenia - complications
Schizophrenia - drug therapy
Schizophrenia - metabolism
Schizophrenic Psychology
title New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A05%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Pharmacotherapy%20Targeting%20Cognitive%20Dysfunction%20of%20Schizophrenia%20via%20Modulation%20of%20GABA%20Neuronal%20Function&rft.jtitle=Current%20neuropharmacology&rft.au=Uehara,%20Takashi&rft.date=2015-01-01&rft.volume=13&rft.issue=6&rft.spage=793&rft.epage=801&rft.pages=793-801&rft.issn=1570-159X&rft.eissn=1875-6190&rft_id=info:doi/10.2174/1570159x13666151009120153&rft_dat=%3Cproquest_pubme%3E1744660030%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1744660030&rft_id=info:pmid/26630957&rfr_iscdi=true